HK Stock Market Move | CARSGEN-B (02171) rose over 4% after earnings, with the mid-term loss attributable to parent company owners narrowing by 11.52% year-on-year.

09:51 19/08/2026

Kejia Pharmaceutical-B (02171) rose over 4% after its earnings announcement, reaching a 4.08% increase at 15.31 HKD, with a transaction amount of 12.5726 million HKD.

CARSGEN-B (02171) rose over 4% after earnings, with a current increase of 4.08%, priced at HKD 15.31, and a trading volume of HKD 12.5726 million. On August 18, CARSGEN-B announced its mid-year results for 2026, reporting a revenue of approximately HKD 61.919 million, a year-on-year increase of 21.5%; an adjusted net loss of HKD 31.927 million, narrowed by 55.53% year-on-year; a loss attributable to equity holders of the parent company of HKD 66.663 million, narrowed by 11.52% year-on-year; and a loss per share of HKD 0.13. The announcement indicated that the revenue growth was mainly due to an increase in sales of Sai Kaize. The reduction in adjusted net loss was primarily attributed to decreased administrative expenses.

HK Stock Market Move | WELLCELL HOLD (02477) fell over 6%. The company anticipates a loss in its interim performance, reversing its previous profit. During the period, the telecommunications business recorded a loss.

HK Stock Market Move | The entire mobile industry chain has collectively declined. It is reported that the iPhone 17 series may increase in price globally before the end of the month, with the highest increase per unit nearing 1,000 yuan.

JP Morgan: Raises target price for HK & CHINA GAS (00003) to HKD 7.75, rating upgraded to "Overweight."